Combination therapy for chronic myeloid leukemia (CML)
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a new combination treatment for people with chronic myeloid leukemia (CML) whose disease is resistant to or intolerant of current standard drugs. The goal is to see if the study drug works better when combined with another drug, and to check its safety.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 74 years old
- You have chronic or accelerated phase CML (a type of blood cancer) with the Philadelphia chromosome or BCR-ABL fusion gene
- You have tried at least one previous TKI therapy (standard pill treatment) and it stopped working or you couldn't tolerate it
- You are generally active and able to care for yourself (ECOG 0-1)
- You are willing to use effective birth control during the study and for 6 months after
- You do not have certain heart problems, recent heart attack, uncontrolled diabetes, or a history of pancreatitis
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares two oral medications, flumatinib and imatinib, to see which is more effective and safer for people newly diagnosed with chronic myeloid leukemia in its early phase. It aims to help doctors choose the best initial treatment.
This study tests a new oral medication for people with chronic myeloid leukemia (CML) who have already tried at least three other treatments without success or with side effects. The goal is to see if this new drug can help control the leukemia.
This trial tests a new combination of three drugs (a third-generation TKI, azacitidine, and a Bcl-2 inhibitor) for people with chronic myeloid leukemia that has progressed to a more advanced phase (myeloid blast phase). The goal is to see if this combination is safe and effective.
This trial tests an experimental drug called TGRX-678 for people with a specific, more advanced stage of chronic myeloid leukemia (CML) called 'accelerated phase.' It’s for patients whose cancer has stopped responding to or who couldn't tolerate earlier targeted therapies (tyrosine kinase inhibitors).
This trial is testing a combination of three drugs (FLAG-Ida, venetoclax, and asciminib) to see if it is effective and safe for people with certain types of leukemia (CML in blast phase or Ph+ AML) that are new or have come back after treatment. The goal is to see if this combination can control the disease and possibly lead to remission.
This trial tests a combination of three drugs (olverembatinib, venetoclax, and azacitidine) for people with a fast-growing form of chronic myeloid leukemia (CML) called blast phase. The goal is to see if this treatment can help control the leukemia when it has moved to a more aggressive stage.
Hear when a new Chronic Myelogenous Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.